<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75710">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02121444</url>
  </required_header>
  <id_info>
    <org_study_id>17101</org_study_id>
    <secondary_id>BF1414DE</secondary_id>
    <nct_id>NCT02121444</nct_id>
  </id_info>
  <brief_title>BAY86-5046 (Betaseron), Non Interventional Studies</brief_title>
  <acronym>BETAEVAL</acronym>
  <official_title>BETAEVAL - The New BETACONNECT® Auto-injector: Adherence and EVALuation of MS Patients Treated With Betaferon®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate adherence to therapy among patients treated with Betaferon
      who are using the BETACONNECT autoinjector.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Adherence measure to Betaferon therapy based on the real BETACONNECT injections</measure>
    <time_frame>up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Adherence to therapy will be defined as applying  ≥80% of prescribed Betaferon dosages, which can be derived from electronic data stored in the BETACONNECT device.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with and evaluation of the BETACONNECT auto-injector recorded by patient questionnaire</measure>
    <time_frame>up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of health related quality of life,measured with the self-administered Functional Assessment of Multiple Sclerosis (FAMS) questionnaire</measure>
    <time_frame>up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Anxiety measured with the self-administered Hospital Anxiety and Depression Scale (HADS)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Depression measured with the self-administered Center for Epidemiologic Studies Depression Scale (CES-D)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Fatigue measured with the self-administered Fatigue Scale for Motor and Cognitive functions (FSMC)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Cognition will be measured by the HCP with the Symbol Digit Modalities Test (SDMT)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local skin reactions recorded by Health Care Provider (HCP) evaluation</measure>
    <time_frame>up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of injection-related specifics such as injection date, time, and speed will be recorded by the BETACONNECT device</measure>
    <time_frame>up to 24 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Treatment-emergent Adverse Events (TEAE)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <description>Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect auto-injector</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon beta-1b (Betaferon, BAY 86-5046)</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BETACONNECT auto-injector.</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population will consist of patients with relapsing remitting multiple sclerosis
        (RRMS) or patients with a clinically isolated syndrome (CIS) who are treated with
        Betaferon or will be treated with Betaferon according to the attending physician's
        decision and for whom the patient and the physician have agreed to use the BETACONNECT
        device.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with the diagnosis of relapsing remitting multiple sclerosis or a clinically
             isolated syndrome.

          -  Patients must be on treatment with Betaferon or the decision to treat patients with
             Betaferon has been made by the attending physician.

          -  Patient and attending physicians must have agreed on the usage of the BETACONNECT
             auto-injector device

          -  Written informed consent must be obtained.

        Exclusion Criteria:

          -  Patients receiving any other disease modifying drug.

          -  Contraindications of Betaferon described in the Summary of Product Characteristics.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayerhealthcare.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>April 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RRMS</keyword>
  <keyword>CIS</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Interferon-beta</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon beta-1b</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
